Duo Xu

Duo Xu

Auto-generated profile, based on publicly available information

Duo Xu

Department of Gastroenterology, Xiangya Hospital Central South University, Changsha, Hunan, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2023 in Gut and Liver
Verified
Journal Article
Open access
PDF file
DXDuo Xu
Duo Xu
ZPZiheng Peng
Ziheng Peng
YLYong Li
Yong Li
QHQian Hou
Qian Hou
YPYu Peng
Yu Peng
XLxiaowei Liu
xiaowei Liu
Duo Xu, Ziheng Peng , Yong Li, Qian Hou, Yu Peng, Xiaowei Liu. Gut and Liver 2024;18:404-13. https://doi.org/10.5009/gnl230093

21 July 2023 in Annals of Medicine
Verified
Journal Article
Open access
ZPZiheng Peng
Ziheng Peng
DXDuo Xu
Duo Xu
YLYong Li
Yong Li
LXLiu Xiaowei
Liu Xiaowei
FLFujun Li
Fujun Li
YPYu Peng
Yu Peng
To investigate the predictive value of the prognostic nutritional index (PNI) for the effectiveness of infliximab (IFX) in patients with Crohn's disease (CD). All data were retrospectively collected from Xiangya Hospital, Central South University between January 2016 and September 2021. Clinical remission at 52 weeks is the primary endpoint. Altogether, 193 CD patients were enrolled. PNI can identify clinical remission (p = 0.004), and the optimal cut-off value of the PNI was 39.2. 92/116 (79.3%) and 44/77 (57.1%) in the high- and low-PNI groups were in clinical remission at week 52 (p = 0.001). Patients with low PNI have poor general health at baseline. The body mass index, hemoglobin, platelet (PLT), serum creatinine, fibrinogen, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Crohn's disease activity index (CDAI), and location of disease significantly differed between the two groups (p < 0.05). PNI was negatively correlated with CRP, ESR, PLT and CDAI (p < 0.05). The lower PNI, smoking history, and higher CDAI at baseline were the independent risk factors of disease activity at 52 weeks (p < 0.05). The high-PNI group is less likely to develop poor outcomes (p = 0.033). The PNI may serve as a novel and promising biomarker in predicting the effectiveness of IFX and contribute to targeted management in CD.

4 November 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
DXDuo Xu
Duo Xu
BLBin Liu
Bin Liu
ZPZiheng Peng
Ziheng Peng
YLYong Li
Yong Li
XLXiaowei Liu
Xiaowei Liu
YPYu Peng
Yu Peng
Objectives: Disease activity assessment is important for Crohn’s disease (CD) management, since it involves the initial and subsequent therapeutic schedule. The purpose of this study is to identify a portable and reliable indicator for assessing and predicting activity and severity of CD. Design: A multicentre, cross-sectional, diagnosis-based study. Data were obtained retrospectively from clinical records. Setting: Patient data for the development cohort and internal validation cohort were collected from the Department of Gastroenterology, Xiangya Hospital, Central South University between January 2017 and June 2021. Patient data for the external validation cohort were collected from the Department of Gastroenterology, Xiangtan Central Hospital between January 2022 and April 2024. Participants: Inpatients diagnosed with CD were potential participants, and those with CD who also had other autoimmune diseases, malignant tumours, pregnancy or lactation were excluded. We identified 224 patients in the development cohort, 96 patients in the internal validation cohort and 80 patients in the external validation cohort. Outcome measure: Demographic data and laboratory examination results were collected and seven integrated indices were established. Mann-Whitney U test, Kruskal-Wallis K test, χ 2 test and multivariate logistic regression analysis were used to identify independent predictors. Receiver operating characteristics curve analysis was used to evaluate the performance of integrated indices in CD activity and severity staging, and Delong’s test was used for comparison. Results: In the development cohort, platelet-to-albumin ratio (PAR) had the largest area under the curve (AUC) in prediction of activity (AUC of 0.753 (0.687–0.819), sensitivity 73.0%, specificity 68.4%, cut-off value 8.02) and was the only possible alternative in prediction of severity (AUC of 0.770 (0.693–0.848), sensitivity 81.2%, specificity 68.4%, cut-off value 9.71). Moreover, PAR demonstrated coherence in the internal validation cohort, effectively predicting activity (AUC 0.737 (0.639–0.835), sensitivity 65.7%, specificity 79.3%, positive predictive value (PPV) 88.0%, negative predictive value (NPV) 50.0%) and severity (AUC 0.720 (0.591–0.848), sensitivity 88.5%, specificity 77.4%, PPV 76.7%, NPV 64.9%). Furthermore, it showed generalisability in the external validation cohort for predicting activity (AUC 0.661 (0.536–0.785), sensitivity 61.9%, specificity 70.6%, PPV 88.6%, NPV 33.3%) and severity (AUC 0.752 (0.619–0.884), sensitivity 73.1%, specificity 64.9%, PPV 59.4%, NPV 77.4%). Conclusions: PAR could be a portable index to assess the activity and severity of CD. Several limitations of this study, such as the limited sample size and potential biases, should be overcome in the future via more extensive validation.